Fda authorizes emergency use of remdesivir for covid-19

The Food and Drug Administration (FDA) on Friday issued an emergency use authorization for Gilead Sciences’ antiviral drug remdesivir as a treatment option for people who are hospitalized

with COVID-19, the illness caused by the new coronavirus. To date, the virus has killed more than 237,000 people worldwide. The news comes just days after the National Institutes of Health

announced preliminary results from an international clinical trial testing remdesivir as a potential treatment for COVID-19. Researchers found that patients with severe illness who received

the drug recovered faster than those who received a placebo. “Results also suggested a survival benefit,” the NIH said in a news release. The mortality rate for the group that received

remdesivir was lower than for the placebo group. The emergency use authorization — which is not the same as official FDA approval — “allows for remdesivir to be distributed in the U.S. and

administered intravenously by health care providers” to treat patients who have low blood oxygen levels or who need breathing support by way of a mechanical ventilator. "Based on

evaluation of the emergency use authorization criteria and the scientific evidence available, it was determined that it is reasonable to believe that remdesivir may be effective in treating

COVID-19, and that, given there are no adequate, approved, or available alternative treatments, the known and potential benefits to treat this serious or life-threatening virus currently

outweigh the known and potential risks of the drug's use,” the FDA said in a news release. During public health emergencies, the FDA has the power to bypass its normally lengthy

approval process to allow “unapproved medical products or unapproved uses of approved medical products” to diagnose, treat or prevent serious or life-threatening diseases or conditions “when

there are no adequate, approved, and available alternatives.” There is no approved treatment for COVID-19 and no vaccine for the coronavirus, which emerged in December and has since

sickened millions worldwide. In March, the FDA authorized the emergency use of two malaria drugs, chloroquine and hydroxychloroquine, to treat COVID-19. Less than a month later, on April 24,

the FDA warned doctors over use of the two antimalarials, citing serious and potentially life-threatening heart rhythm problems. In Friday's announcement, FDA Commissioner Stephen Hahn

said, “Today's action is an important step in our efforts to collaborate with innovators and researchers to provide sick patients timely access to new therapies where appropriate,

while at the same time supporting research to further evaluate whether they are safe and effective.”